期刊文献+

胃肠道间质瘤46例诊治分析 被引量:2

Diagnosis and treatment of 46 patients with gastrointestinal stromal tumors
暂未订购
导出
摘要 目的探讨胃肠道间质瘤的临床特点及其诊治方法。方法回顾性分析我院2000年1月-2007年10月收治的胃肠道间质瘤46例的临床资料。结果本组46例均手术治疗。术后随访6月~5年30例,复发7例,转移3例,再次手术7例。全组无手术死亡病例。术后并发胰瘘1例、细菌性腹膜炎1例、切口裂开1例,均治愈。结论外科手术和分子靶向治疗是胃肠道间质瘤的主要治疗手段。对复发和转移者应争取再次手术,同时联合分子靶向治疗。 Objective To study clinical characteristics, diagnosis and treatment of gastrointestinal stromal tumors(GIST). Methods The clinical data of 46 cases of GIST admitted in our hospital from Jan. 2000 to Oct. 2007 were retrospectively analyzed. Results All 46 patients in this group were treated surgically. During a period of postoperative follow-up of 6 months to 5 years, recurrence occurred in 7 cases, metastasis in 3 cases, re-operation was done in 7 cases. There were no operative deaths. Postoperative complications included pancreatic fistula( 1 case), bacterial peritonitis(1 case), disruption of wound(1 case) ,all of them were cured. Conclusion Surgical operation and molecular targeted therapy are the main means to treat GIST. The patients who recur and have metastasis had better undergo second operation, at the same time molecular targeted therapy was given.
出处 《腹部外科》 2008年第3期167-168,共2页 Journal of Abdominal Surgery
关键词 胃肠道间质肿瘤 消化系统外科手术 手术后并发症 Gastrointestinal stromal tumors Digestive system surgical procedures Postoperative complications
  • 相关文献

参考文献5

  • 1Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course and prognostication in the preimatinib mesylate era: A population-based study in western sweden. Cancer, 2005,103:821-829.
  • 2Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol,2006,18,386-395.
  • 3Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004,22 : 3813-3825.
  • 4Fletcher CD, Berman J J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approch. Hum Pathol, 2002, 33 : 459-465.
  • 5秦新裕,刘凤林.胃肠道间质瘤的研究进展与展望[J].中华普通外科杂志,2007,22(8):561-563. 被引量:34

二级参考文献7

  • 1詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:87
  • 2Fletcher CD, Berman J J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002,33 : 459- 465.
  • 3Miettinen M, Makhlouf H, Lasota J, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 casesbefore imatinib with long-term follow-up. Am J Surg Pathol, 2006, 30 : 477- 489.
  • 4Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29 : 52-68.
  • 5Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib in patients with metastatic phase-Ⅲ Sarcoma Group Study S0033. J Clin Oncol, 2004: 9005.
  • 6Blay JY, Le Cesne AL, Ray-Coquard I, et al. Prospective muhicentric randomized phase Ⅲ study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the french sarcoma group. J Clin Oncol, 2007, 25 : 1107-1113.
  • 7Casali PG, Garrett CR, Blackstein ME, et al. Updated results from a phase III trial of sunitinib in GIST patients for whom imatinib therapy has failed due to resistance or intolerance. J Clin Oncol, 2006,24: 9513.

共引文献33

同被引文献19

  • 1彭卫军,蒋朝霞,师英强,李小秋.CT与MRI对直肠间质瘤的诊断价值[J].中国实用外科杂志,2006,26(8):610-612. 被引量:15
  • 2秦新裕,沈坤堂.胃肠道间质瘤的手术治疗[J].腹部外科,2007,20(1):10-12. 被引量:6
  • 3Joensuu H,Roberts PJ,Sarlomo-Rikala M,et al.Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med,2001,344:1052-1056.
  • 4Choi H,Charnsangavej C,Faria SC,et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:proposal of new computed tomography response criteria.J Clin Oncol,2007,25:1753-1759.
  • 5Benjamin RS,Schoffski P,Hartmann JT,et al.Efficacy and safety of motesanib,an oral inhibitor of VEGF,PDGF,and Kit receptors,in patients with imatinib-resistant gastrointestinal stromal tumors.Cancer Chemother Pharmacol,2011,68:69-77.
  • 6Dematteo RP,Ballman KV,Antonescu CR,et al.Adjuvant imatinib mesylate after resection of localised,primary gastrointestinal stromal tumour:a randomised,double-blind,placebo-controlled trial.Lancet,2009,373:1097-1104.
  • 7Joensuu H,Eriksson M,Sundby Hall K,et al.One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor:a randomized trial.JAMA,2012,307:1265-1272.
  • 8Le Cesne A,Ray-Coquard I,Bui BN,et al.Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment:an open-label multicentre randomised phase 3 trial.Lancet Oncol,2010,11:942-949.
  • 9Wang D,Zhang Q,Blanke CD,et al.Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors:long-term follow-up results of Radiation Therapy Oncology Group 0132.Ann Surg Oncol,2012,19:1074-1080.
  • 10Patrikidou A,Chabaud S,Ray-Coquard I,et al.Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST:results of the BFR14 prospective French Sarcoma Group randomised,phase III trial.Ann Oncol,2013,24:1087-1093.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部